Alzamend Neuro, Inc. (ALZN)
ALZN moved a median of -0.59% 30 minutes after news, and -1.25% by the close. How ALZN actually reacts to news — the realized, point-in-time move the market made, measured across 189 labeled events over the last three years with zero look-ahead.
ALZN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.14% | 31% | 176 |
| 30-min | -0.59% | 29% | 187 |
| 60-min | -1.21% | 25% | 188 |
| to close | -1.25% | 38% | 189 |
| Middle 50% of ALZN reactions | -2.71% to +0.39% |
|---|---|
| Median reaction (30-min) | -0.59% |
| Measured reactions | 189 |
Half of all Alzamend Neuro, Inc. news events land between -2.71% and +0.39% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ALZN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALZN's baseline. Nothing else.
Recent ALZN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form RW Alzamend Neuro, Inc. | SEC filing · Form RW | SEC EDGAR | +4.38% | -2.19% | |
| Form 8-K Alzamend Neuro, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +4.60% | |
| Alzamend Neuro Regains Compliance with Nasdaq Listing Standards | Press release | PR Newswire | +0.01% | +2.23% | |
| Form 10-Q Alzamend Neuro, Inc. For: Jul 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.40% | +2.99% | |
| Form PRE 14A Alzamend Neuro, Inc. For: Oct 19 | SEC filing · Form PRE | SEC EDGAR | — | -3.61% | |
| Form S-1 Alzamend Neuro, Inc. | SEC filing · Form S-1 | SEC EDGAR | -1.66% | +2.65% | |
| Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC | Press release | PR Newswire | -0.64% | +4.49% | |
| Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain | Press release | PR Newswire | -0.66% | +0.00% | |
| Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending | Press release | PR Newswire | +0.00% | +5.07% | |
| Form 8-K Alzamend Neuro, Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.07% | |
| Form 10-K Alzamend Neuro, Inc. For: Apr 30 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -3.82% | |
| Form 8-K Alzamend Neuro, Inc. For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | -2.24% | +0.75% | |
| Form 8-K Alzamend Neuro, Inc. For: Apr 17 | SEC filing · Form 8-K | SEC EDGAR | -4.42% | -1.77% | |
| Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital | Press release | PR Newswire | +4.18% | +1.82% | |
| Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions | Press release | PR Newswire | -13.61% | -21.47% | |
| Form 8-K Alzamend Neuro, Inc. For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.64% | |
| Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital | Press release | PR Newswire | +0.00% | -7.89% | |
| Form 10-Q Alzamend Neuro, Inc. For: Jan 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.79% | |
| Form 8-K Alzamend Neuro, Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.94% | |
| Form DEF 14A Alzamend Neuro, Inc. For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | +0.97% | -2.43% | |
| Form DEFA14A Alzamend Neuro, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.97% | -2.43% | |
| Form PRE 14A Alzamend Neuro, Inc. For: Apr 17 | SEC filing · Form PRE | SEC EDGAR | -0.38% | -2.54% | |
| Form 10-Q Alzamend Neuro, Inc. For: Oct 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.84% | -0.46% | |
| Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital | Press release | PR Newswire | -3.53% | -9.41% | |
| Form 8-K Alzamend Neuro, Inc. For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | -3.53% | -9.41% | |
| Form 8-K Alzamend Neuro, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +3.57% | |
| Form 8-K Alzamend Neuro, Inc. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -4.66% | -6.03% | |
| Form 8-K Alzamend Neuro, Inc. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | +2.12% | |
| Form 10-Q Alzamend Neuro, Inc. For: Jul 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.61% | +4.35% | |
| Form 8-K Alzamend Neuro, Inc. For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | +1.53% | +5.46% | |
| Alzamend Neuro to Present at the 2025 Military Health System Research Symposium | Press release | GlobeNewswire | -3.63% | -4.15% | |
| Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs | Press release | GlobeNewswire | +0.55% | -3.53% | |
| Form 8-K Alzamend Neuro, Inc. For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -0.33% | |
| Form 10-K Alzamend Neuro, Inc. For: Apr 30 | SEC filing · Form 10-K | SEC EDGAR | +0.55% | -3.53% | |
| Form 8-K Alzamend Neuro, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | +0.99% | |
| Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule | Press release | GlobeNewswire | +0.00% | -3.74% | |
| Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital | Press release | GlobeNewswire | +2.17% | -29.53% | |
| Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital | Press release | GlobeNewswire | -1.41% | +1.41% | |
| Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital | Press release | GlobeNewswire | -5.88% | -31.70% | |
| Alzamend Neuro Announces Reverse Stock Split | Press release | GlobeNewswire | -0.73% | -3.57% | |
| Form 8-K Alzamend Neuro, Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +21.87% | |
| Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital | Press release | GlobeNewswire | -4.13% | -12.09% | |
| Form 8-K Alzamend Neuro, Inc. For: Apr 25 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -2.66% | |
| Form EFFECT Alzamend Neuro, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.45% | -8.62% | |
| Form S-1/A Alzamend Neuro, Inc. | SEC filing · Form S-1 | SEC EDGAR | -1.82% | -3.64% | |
| Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital | Press release | GlobeNewswire | -7.08% | -10.62% | |
| Form DEFA14A Alzamend Neuro, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -3.76% | +0.86% | |
| Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital | Press release | GlobeNewswire | -5.56% | +4.43% | |
| Form DEFA14A Alzamend Neuro, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -5.56% | +4.43% | |
| Form DEF 14A Alzamend Neuro, Inc. For: Apr 25 | SEC filing · Form DEF | SEC EDGAR | +0.44% | -1.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALZN section they belong to.
Where else ALZN is measured.
ALZN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alzamend Neuro, Inc.'s median reaction calculated?
Every labeled ALZN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 189 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 29% of ALZN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALZN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.